Videos

Experts in breast cancer discuss efficacy data from the IMpassion130 clinical trial.

Elizabeth Mittendorf, MD, PhD, reviews the case of a 53-year-old woman with PD-L1+ TNBC breast cancer and the panel discusses relevant clinical trial data.

Ingrid Mayer, MD, MSCI, presents the case of a patient with high-risk HR+/HER2+ breast cancer who develops recurrence after a long disease-free interval.

Thomas Bachelot, MD, PhD, discusses therapies available for patients with HER2-positive breast cancer and brain metastases.

Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-Positive thyroid cancer.

Mitul Gandhi, MD, discusses the current landscape for patients with diffuse large B-cell lymphoma and what may be coming in the future.

Nadia Harbeck, MD, PhD, discusses how the monarchE trial, which evaluated the efficacy of endocrine therapy with or without abemaciclib, will change breast cancer treatment.

Looking ahead, Loretta Nastoupil, MD, reviews the future direction and unmet needs in the management of relapsed/refractory follicular lymphoma (R/R FL).

Dr Loretta Nastoupil describes best practices for managing the side effects of tazemetostat in patients with R/R FL.

Loretta Nastoupil, MD, discusses the use of tazemetostat in patients with and without an EZH2m.

Loretta Nastoupil, MD, describes the challenges of selecting treatment beyond the second-line.

Loretta Nastoupil, MD, describes the challenges of selecting treatment beyond the second-line.

A key opinion leader in the treatment of FL provides insight on the decision of whether to add maintenance therapy to the treatment regimen.

Loretta Nastoupil, MD, discusses first-line therapy options for patients with newly diagnosed follicular lymphoma (ND FL).

Loretta Nastoupil, MD, describes the role of molecular testing used in risk stratification of patient with FL

Loretta Nastoupil, MD, reviews the case of a 75-year-old woman with relapsed/refractory follicular lymphoma (R/R FL).

Expert hematologist/oncologists discuss the use of early PI3K inhibitors in the management of R/R follicular lymphoma (FL) and MZL (marginal zone lymphoma).

Ian W. Flinn, MD, PhD, leads the discussion on the various PI3K isoforms and their role in lymphoma.

Ruben Mesa, MD, and panel discuss considerations for optimizing therapy in high risk myelofibrosis.

Experts in myelofibrosis present safety and efficacy data from a clinical trial of fedratinib in patients with high risk myelofibrosis.

Dr Jamile Shammo presents clinical trial data on the efficacy and safety of ruxolitinib in patients with high risk myelofibrosis.

Experts in MPN review data on predictors of response to ruxolitinib in high risk myelofibrosis.

Jamile Shammo, MD, reviews prognostic models in myelofibrosis.

Dr Jamile Shammo reviews the case of a 72-year-old man with primary myelofibrosis.

Experts in the management of breast cancer review some trials leading to the future of personalized treatment for HER2+ breast cancer.

Andrew Seidman, MD, follows the patient after TCHP therapy and discusses the risk of recurrence with the experts.

Ingrid Mayer, MD, MSCI, and panel share the benefits of subcutaneous HP instead of IV HP therapy, particularly for the patients’ quality of life.

The panel of experts reviews the use dual HER2-targeted therapy in HER2+ breast cancer.

Experts in breast cancer management discuss the use of anthracycline and risk of the cardiac toxicities.

Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.